(R)-CR8

(R)-CR8

Chemicals & Biochemicals

Article No

AG-MR-C0003-M050

Size

50 mg

Shipping Information

RT

Article No

AG-MR-C0003-M050

Size

50 mg

Shipping Information

RT

Specifications

CAS No 294646-77-8
MW 431.5
Article No AG-MR-C0003-M050
Country Availability SE, FI, DK, NO, IS, EE, LV, LT
Description (R)-CR8
Supplier Adipogen Life Sciences
Format Powder
Notes Chemical. CAS: 294646-77-8. Formula: C24H29N7O. MW: 431.5. Potent and selective inhibitor of cyclin dependent kinases CDK1, CDK2, CDK5, CDK7 and CDK9. Apoptosis inducer. Inhibits the proliferation of various cancer cell lines. Casein kinase 1 (CK1delta/epsilon) and glycogen synthase kinase (GSK-3alpha/beta) inhibitor. Potential anti-inflammatory compound. Potential antidiabetic compound.|Potent and selective inhibitor of cyclin dependent kinases CDK1, CDK2, CDK5, CDK7 and CDK9. Apoptosis inducer [1, 3, 4]. Inhibits the proliferation of various cancer cell lines [1]. Casein kinase 1 (CK1delta/epsilon) and glycogen synthase kinase (GSK-3alpha/beta) inhibitor [1, 2]. Potential anti-inflammatory compound. Potential antidiabetic compound.
Molecular Formula C24H29N7O
Alias Names 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurine
Product Type Chemicals & Biochemicals
Purity >98%
Research area Cell Death
Shipping Information RT
Size 50 mg
Solubility Soluble in DMSO or ethanol.
Stability Stable for at least 2 years after receipt when stored at -20°C.
Storage -20°C, 4°C
Technical Specifications Chemical. CAS: 294646-77-8. Formula: C24H29N7O. MW: 431.5. Potent and selective inhibitor of cyclin dependent kinases CDK1, CDK2, CDK5, CDK7 and CDK9. Apoptosis inducer. Inhibits the proliferation of various cancer cell lines. Casein kinase 1 (CK1delta/epsilon) and glycogen synthase kinase (GSK-3alpha/beta) inhibitor. Potential anti-inflammatory compound. Potential antidiabetic compound.
Product Page Updated 2024-02-01T08:25:01.492Z

Documentation

References

Show more
Shipping info
The delivery time for this item is approximately 5-8 business days. Read more